EssilorLuxottica released three-year clinical trial results of its Essilor Stellest lens for myopia at the 18th International Myopia Conference (IMC) 2022 in Rotterdam, Netherlands, last week.
The results showed that the lenses “continue to exhibit strong efficacy in slowing myopia progression and axial elongation in the third year of the clinical trial”, stated the company – a diamond sponsor of the IMC.
EssilorLuxottica’s satellite session was facilitated by Dr Mark A. Bullimore of the University of Houston, and Olga Prenat, EssilorLuxottica head of medical marketing, professional relations and vision care education. The session, titled ‘Essilor Stellest lens. New benefits of myopia control spectacle lenses’, saw presentations from EssilorLuxottica’s R&D experts, Dr Damien Paillé and Dr Björn Drobe.
The session also had presentations from Dr Padmaja Sankaridurg, head of the myopia programme at the Brien Holden Vision Institute, titled ‘Essilor Stellest lens: Results from a randomised, double-blind, cross-over clinical trial’, and from Dr Bullimore on the impact of spectacle lenses for myopia control on visual function, and myopia control in other ethnicities. There was a plenary talk by Dr Drobe, titled ‘Myopia control efficacy of spectacle lenses with highly aspherical lenslets: three-year results’.
The clinical trial was conducted at the Eye Hospital of Wenzhou Medical University in Wenzhou, China, where 151 children from the first two years of the study were switched to spectacle lenses with highly aspherical lenslets – while a new set of 56 children were recruited and wore single vision lenses.
Key highlights include:
● The lenses saved more than one dioptre of myopia on average over three years, demonstrating “conclusive evidence that they remain effective in slowing down myopia progression in children in the third year”
● Children who wore Essilor Stellest lenses full-time (at least 12 hours a day) saw a marked increase in myopia control efficacy
● The lenses are effective in slowing myopia progression and axial elongation in older children
Norbert Gorny, co-chief operating officer at EssilorLuxottica, said: “We are extremely encouraged to have such conclusive data showing that Essilor Stellest lenses continue to slow down myopia progression in children after three years. With the growing prevalence of myopia and associated risk of ocular conditions, we are proud to be at the forefront of myopia management with our lenses to move the needle in the fight against myopia. The lens is now available in more than 20 countries, and we will continue to expand our footprint in the future and help advance knowledge and education of myopia management to ensure that everyone understands the importance and benefits of managing myopia early and proactively in children.”